Talking With The Region’s Top CEOs and Business Leaders

Wall Street Club TV: Today on Wall Street Club TV we are welcoming Mr. Dwight Egan,CEO of Co-Diagnostics Inc, a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests. Co-Diagnostics is headquartered in Salt Lake City, Utah and trades on NASDAQ under the symbol CODX. Mr. Egan, thank you for hosting us today.

Mr. Dwight Egan, CEO : My pleasure.

WSCtv : Dwight, we’d like to begin by asking you about your most recent press release announcing a license agreement with LGC, Biosearch, in which you stated that “the importance of the validation for our company and technology cannot be overstated.” Would you mind telling us a little bit about why that is the case?

Mr. Egan : This license agreement we signed LGC is the culmination of about a year of serious research and development, where both companies have validated the technology of our CoPrimers. We have a very important technology that we call CoPrimers that is able to do some very remarkable things in molecular diagnostics. So I think the first take away from the LGC signing is that it validates the reality and the importance of our technology. Along with that, during the process of this validation, we also obtained our patent for the technology, again showing the uniqueness of the product. And so, the first take-away is just total validation of what it is that we are doing, and that what we are able to do in our labs has been able to be duplicated in other labs with very high-level scientific research capabilities.

WSCtv : Okay, it sounds like the importance speaks for itself. What impact do you think this will have ultimately on your company?

Mr. Egan :  Well now that we have the patent protection and the validation with people like LGC and also the work we are doing with Stanford University, we are in a position now to offer thisproduct worldwide. LGC has a very wide footprint around the globe, serving around a hundred and sixty different countries, with over 20,000 customers and about 12,000 different laboratories they service, both big and small. So we are now able to unleash our product in all those areas with a secure patent and with the validation from a wonderful partner in the field like LGC.

WSCtv : Absolutely. And a moment ago you mentioned the CoPrimer patent that you had received, and it does seem as though the LGC announcement comes on the heels of several weeks of encouraging news, including as you mentioned the patent, but also including the CE mark for Zika, and now culminating in this LGC announcement. How would you summarize what these achievements mean for your company,for Co-Diagnostics?

Mr. Egan : Well you know, we have cut our teeth in infectious diagnostics. The first place we wanted to manifest the strength of our technology was in creating infectious disease molecular diagnostics tests that were very high grade, but available to, particularly the undeveloped world for a fraction of the cost they would typically be paying for competitor’s products. So, the work in validating CoPrimers is also been validating our products for things like tuberculosis, and Zika, and we have several others that are quickly going to be announced that have to do with validating, with a CE Mark, the products that we are making available. So, you know, at the end of the day we have three different verticals that we are going to be moving in. The first is this area of infectious disease, the second is the area of agriculture, as manifest by the license agreement that we signed with LGC, and the third is in the area of liquid biopsy, because the technology that we have, the CoPrimer technology, has broad ramifications for liquid biopsy.

WSCtv : It sounds like you are building quite a lot of momentum in this regard as well. Where do you see that momentum leading?

Mr. Egan : Well of course, we see it leading to increased sales and profits. We are involved in three very strong verticals in addition to the opportunity to license our technology and our software to thousands of labs around the world who are doing research and development in very diverse areas of the genome, whether it’s animal,plant,or human.So, we are excited that during this fourth quarter we are going to be coming into revenues,and then continually growing that through 2019 and on to the future.We have done this with a very small group of people with a very hot technology.And so when you look up what we have accomplished in a very short time, in terms of bringing a technology to the floor with validation from solid third-party players and getting products into the market, we’ve moved very quickly and without a whole bunch of sunk costs in getting it done. So, if you compare us with other companies that are out there in terms of what it costs us to deliver the goods, we are going to come out very favorably.So we are very excited about this era of expansion that we see in front of us as we come into revenues and go into these three verticals head-on.

WSCtv : Well we certainly look forward to seeing that. And before we let you go, as we were preparing for this interview, we noticed that just recently you launched a new website. It sounds like you have a full plate as it is. With every else that you have going on, why did you feel that now it was necessary to do that, to take that step?

Mr. Egan : Well for us it was necessary to make sure that we could recast the nice things that we have learned about our technology over the last couple of years. You know, we knew a coupleof years ago that we had a very strong suit in multiplexing. Sort of a unique domain really in all the world in terms of what our CoPrimers were able to do in multiplexing. But we’ve since learned how well our CoPrimers do in things like SNP detection, and also in multiplexing the SNP detection, as well as the broad ramifications and applications that we have in next-gen sequencing. And all of these have made it so we have the ability to go not only into infectious disease, but into areas like liquid biopsy, and agriculture. Of course there are several other places that we could go, but we are sort of limiting, given the bandwidth of our company, where our focus to these three verticals.

WSCtv : Of course. And Dwight, thank you so much for taking the time to put your recent advancements in context for us here at the Wall Street Club and for our followers, but also for your shareholders and followers as well. Thank you again.

Mr. Egan : Thank you.